Checkpoint Therapeutics, Inc. Quarterly Debt-to-equity in % from Q2 2017 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Checkpoint Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2017 to Q3 2024.
  • Checkpoint Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was -155 %, a 14.2% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 -155 -19.2 -14.2% Sep 30, 2024
Q2 2024 -143 +30.7 +17.6% Jun 30, 2024
Q1 2024 -143 +163 +53.3% Mar 31, 2024
Q4 2023 -128 -1.63K -109% Dec 31, 2023
Q3 2023 -135 -307 -179% Sep 30, 2023
Q2 2023 -174 -256 -313% Jun 30, 2023
Q1 2023 -305 -351 -766% Mar 31, 2023
Q4 2022 1.5K +1.47K +5010% Dec 31, 2022
Q3 2022 172 +153 +808% Sep 30, 2022
Q2 2022 81.9 +65.4 +396% Jun 30, 2022
Q1 2022 45.8 +25.5 +125% Mar 31, 2022
Q4 2021 29.4 +1.83 +6.64% Dec 31, 2021
Q3 2021 18.9 -15 -44.3% Sep 30, 2021
Q2 2021 16.5 -37.9 -69.7% Jun 30, 2021
Q1 2021 20.3 -43.4 -68.1% Mar 31, 2021
Q4 2020 27.6 -54 -66.2% Dec 31, 2020
Q3 2020 33.9 -80.8 -70.5% Sep 30, 2020
Q2 2020 54.4 -24.8 -31.3% Jun 30, 2020
Q1 2020 63.7 +5.59 +9.62% Mar 31, 2020
Q4 2019 81.6 +39.2 +92.4% Dec 31, 2019
Q3 2019 115 +81.5 +245% Sep 30, 2019
Q2 2019 79.2 +48.5 +158% Jun 30, 2019
Q1 2019 58.1 +31.2 +116% Mar 31, 2019
Q4 2018 42.4 +19.1 +82.1% Dec 31, 2018
Q3 2018 33.2 +16.3 +96.2% Sep 30, 2018
Q2 2018 30.7 +17.1 +125% Jun 30, 2018
Q1 2018 26.9 Mar 31, 2018
Q4 2017 23.3 Dec 31, 2017
Q3 2017 16.9 Sep 30, 2017
Q2 2017 13.6 Jun 30, 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.